Senzime receives the first million order from South Korea
Senzime signed a distribution agreement with Unimedics in March 2018 communicating expected launch during 2019. This order is the first out of a guaranteed sales target as market launch is approaching.
There are over 3000 hospitals in South Korea and annually 1.3 million operations are performed with anesthesia, of which muscle relaxants are used in more than half of them. TetraGraph is used for monitoring of this patient category. For each monitoring occasion, in addition to the instrument itself, TetraSens is used which is a disposable sensor also developed and sold by Senzime. This initial order includes 50 TetraGraph instruments. Senzime will train 70 sales representatives from Unimedics in June.
“We have an actual medical need in an area with up to 40% complication rates. During this year we have worked closely with our Korean distributor, and we are pleased that sales are about to start. We expect further orders from Korea before year end” says Pia Renaudin, CEO of Senzime AB.
For further information, please contact:
Pia Renaudin, CEO of Senzime AB
Tel: +46 (0)70-813 34 17, email: firstname.lastname@example.org
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, email@example.com, is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on May 29th, 2019 13:15